THE FAST-MI 2005-2010-2015 REGISTRIES IN LIGHT OF THE ODYSSEY TRIAL: POTENTIAL INDICATIONS FOR PCSK9 INHIBITION IN ACS PATIENTS

Background. The ODYSSEY trial showed the benefit of adding alirocumab to high intensity statins in patients (pts) with recent acute coronary syndrome. Treatment effect was greater in pts with LDL-C >100mg/dL. The real-life burden of patients eligible for alirocumab and their risk profile is unclear